Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
Manufacturing
